What to Do If Your Zepbound Pen Malfunctions: A Step-by-Step Troubleshooting Guide

Direct answer (40-60 words)

If your Zepbound pen does not deliver a dose, do not re-inject, do not extract liquid, and do not retry with the same pen. Document what happened (no first click, no second click, no liquid, lock ring stuck), photograph the device, contact Lilly Customer Service at 1-800-545-5979, and call your provider for replacement guidance.

Table of contents

1. The 30-second answer
2. Two Zepbound delivery formats and how they fail differently
3. The single-dose pen: signals you should hear and feel
4. The KwikPen multi-dose: priming and dose-knob failure modes
5. Six common malfunctions and what each one means
6. What to do in the first 5 minutes after a failed injection
7. When to take a replacement dose and when to skip
8. Reporting to Lilly and your provider
9. Storage and handling errors that look like malfunctions
10. Alternative if pen access keeps failing: compounded tirzepatide
11. FAQ
12. Footer disclaimers

Two Zepbound delivery formats and how they fail differently

Zepbound is made by Eli Lilly. It currently ships in three formats:

1. Single-dose pen. A pre-filled, single-use autoinjector. You open the lock ring, press it against your skin, push the purple button, and listen for two clicks (first click starts injection, second click ends it).
2. Single-dose vial. A glass vial of solution drawn up with a U-100 insulin syringe.
3. KwikPen multi-dose pen. A re-usable pen that holds 4 weekly doses. You attach a fresh needle each week, prime the pen, dial the dose knob to "1," and press it against your skin for a 5-second hold.

The malfunctions that show up in patient reports are different across the three. The original TrimRx article mixed them together. They should not be.

This guide covers the single-dose pen and the KwikPen. If you use a vial and syringe, see our tirzepatide vial dosing reference.

The single-dose pen: signals you should hear and feel

The Zepbound single-dose pen is designed to give you two confirmation clicks during a successful injection.

The expected sequence:

1. Remove the gray base cap.
2. Press the clear base of the pen firmly against your skin.
3. Turn the lock ring from "lock" to "open."
4. Press and hold the purple button.
5. Listen for the first click. This is the injection starting.
6. Continue holding for up to 10 seconds. The viewing window changes from clear to gray as the dose is delivered.
7. Listen for the second click. This confirms the dose is complete.
8. Withdraw the pen from your skin.

What it should feel like: moderate pressure against your skin, a single button-press, and two distinct clicks separated by several seconds. The viewing window should turn fully gray.

What might go wrong:

• The first click never sounds (no injection started).
• The first click sounds but the second never does (injection may be incomplete).
• The window does not change from clear to gray (no medication was delivered).
• The lock ring will not turn (mechanical fault).
• The button will not depress (mechanical fault).
• Liquid leaks at the base of the pen (seal failure).

If any of these happens, follow the troubleshooting protocol below.

The KwikPen multi-dose: priming and dose-knob failure modes

The KwikPen consolidates four weekly doses into one device. Failures here usually involve priming, dose-knob mechanics, or needle attachment.

The expected weekly sequence:

1. Attach a new KwikPen-compatible needle.
2. Prime the pen if it is the first use, or check the flow before each subsequent dose per the IFU.
3. Dial the dose knob until "1" appears in the window.
4. Press the pen firmly against your skin.
5. Press the dose knob in fully.
6. Count to 5 while holding.
7. Withdraw and dispose of the needle.

Common KwikPen failures:

• Dose knob will not dial to "1" (cartridge near end of life or mechanical fault).
• No drop forms during priming after multiple attempts.
• The dose knob springs back partially when pressed.
• Needle clogs during injection.
• Cap will not come off.

The KwikPen is designed for weekly use across 4 weeks. After the fourth dose, the dial will lock at zero and the pen is done.

Six common malfunctions and what each one means

1. No first click on the single-dose pen. The injection mechanism did not engage. Possible causes: lock ring not fully turned to open, pen not pressed hard enough against skin, or internal mechanical failure. Action: do not press harder repeatedly. Withdraw, set the pen aside, and contact Lilly and your provider for a replacement.

2. First click but no second click. The injection started but did not complete. The dose may be partially delivered. Action: do not re-inject with the same pen. Check the viewing window. If it is partly gray, a partial dose was delivered. Document and contact your provider for guidance on whether to take a replacement dose.

3. The viewing window does not change. No medication was delivered. The pen is defective. Action: discard in a sharps container, contact Lilly, and follow your provider's guidance on a replacement dose.

4. KwikPen dial will not turn to "1." Either the cartridge is empty (you have already used 4 doses) or the dial mechanism has failed. Action: confirm how many doses you have taken. If you have used fewer than 4, contact Lilly and your provider.

5. Liquid leaks during or after injection. The seal between the cartridge and the needle hub has failed. Action: discard the pen. The dose was likely incomplete. Contact your provider.

6. The lock ring or cap will not move. A mechanical defect. Do not force it (forcing can break the device and create a sharps hazard). Set the pen aside and contact Lilly for a replacement.

What to do in the first 5 minutes after a failed injection

1. Do not re-inject with the same pen. Even if you suspect a partial dose, re-injecting with the same device risks dose duplication, contamination, or further mechanical failure.
2. Document what you observed. Write down or photograph the date, time, which click sequence you heard, whether the window changed color, any visible liquid leak, and the pen's lot number (printed on the label).
3. Set the pen aside in a clean, secure location. Lilly may ask you to return it for analysis.
4. Check the viewing window. Clear means no dose was delivered. Fully gray means the full dose was likely delivered. Partly gray suggests a partial dose.
5. Look for any liquid on your skin or clothing. A wet injection site usually means medication leaked instead of injecting subcutaneously.

The decision about whether to take a replacement dose belongs to your provider. Do not self-correct.

When to take a replacement dose and when to skip

This is a clinical decision, not a self-decision. Your provider will weigh:

• How much of the dose was likely delivered.
• Where you are in your titration schedule.
• Your tolerance to the prescribed dose.
• The half-life of tirzepatide (about 5 days), which means a missed weekly dose has limited short-term effect.

General patterns providers tend to follow (yours may differ):

• Clear viewing window, no medication on skin: likely no dose delivered. Provider may authorize a replacement dose with a fresh pen.
• Fully gray window, no leak: full dose likely delivered. Continue as normal.
• Partial gray, visible leak: partial dose delivered. Provider often skips to next scheduled dose to avoid stacking.

Do not take a second pen on your own. Doubling a tirzepatide dose can cause severe nausea, vomiting, and dehydration.

Reporting to Lilly and your provider

Lilly Customer Service: 1-800-545-5979 (US). They handle defect reports and replacement coordination for FDA-approved Zepbound products. Have ready: pen lot number, NDC, what malfunctioned, and your prescription details.

FDA MedWatch: voluntary adverse event reporting at fda.gov/medwatch. Use this if the malfunction caused harm or if you want to add to FDA's safety database. Reporting is anonymous if you choose.

Your provider: for clinical decisions about replacement doses, schedule adjustment, and any side effects.

Your pharmacy: for replacement coordination and insurance authorization. Many pharmacies will replace a defective pen at no additional cost, but the process varies.

Document everything in writing. If your insurance later questions a replacement claim, the lot number and Lilly case number will resolve it faster than memory will.

Storage and handling errors that look like malfunctions

Some "malfunctions" are actually storage damage. Common patterns:

Frozen pen. If the pen was frozen at any point (refrigerator set too cold, mailbox in winter, freezer pack contact during shipping), the medication is no longer usable. Frozen tirzepatide loses potency and can produce immunogenic byproducts. Even if the pen looks intact, discard it.

Heat-exposed pen. If the pen was above 86°F for any extended period (car dashboard in summer, heated mailbox, direct sunlight), the medication may have degraded. Visual inspection cannot confirm potency loss. Discard and replace.

Expired pen. Past the printed expiration, the pen is not safe to use. Sterility and potency cannot be guaranteed.

Cloudy or discolored solution. Tirzepatide should be clear and colorless. Cloudiness, color change, or visible particles mean the pen is compromised. Discard.

If your pen "malfunctions" but you cannot rule out improper storage, treat it as a storage-damage event rather than a manufacturing defect when you report it.

Alternative if pen access keeps failing: compounded tirzepatide

Some patients move to compounded tirzepatide because of recurring pen access issues, insurance denials, or supply gaps. Compounded tirzepatide differs from the branded pen in three ways:

1. Drawn from a vial with a U-100 insulin syringe rather than a pre-loaded autoinjector.
2. Dose is read off the syringe markings in mL or units, eliminating click-counting and pen-mechanism failure modes.
3. Pricing is typically flatter and lower than retail brand-name pens, often $229 to $349 monthly.

Compounded tirzepatide is not FDA-approved, has not undergone the same review process as Zepbound, and is not interchangeable with branded tirzepatide for FDA-approval purposes. Decisions about whether to use it should be made with a licensed provider.

For more, see our compounded tirzepatide cost reference and the units-to-mg conversion guide.

FAQ

My Zepbound pen did not click. What do I do?

Withdraw the pen from your skin without re-pressing. Check the viewing window. If it is clear, no dose was delivered. Document the event (date, lot number, what you observed), set the pen aside, and contact Lilly Customer Service at 1-800-545-5979 and your provider before taking any replacement dose.

Can I re-use a Zepbound pen if it failed the first time?

No. The single-dose pen is designed for one injection only. The KwikPen is designed for weekly use across 4 doses. If the pen has malfunctioned, set it aside for Lilly's review and use a fresh device only after your provider authorizes it.

What if I heard the first click but not the second?

The injection started but did not complete. The dose was likely partial. Do not re-inject with the same pen. Document the event and contact your provider for guidance on whether to take a replacement dose.

The viewing window is clear after I injected. Did I get my dose?

Probably not. A clear or only partly gray window indicates the medication was not fully delivered. Contact Lilly and your provider before taking another dose.

My Zepbound pen leaked liquid during injection. What does that mean?

The seal between the cartridge and the needle has failed, and the dose was likely incomplete. Discard the pen, document the event, and contact your provider before taking a replacement dose.

Can I take a second Zepbound dose right away if my first pen failed?

Only with provider authorization. Doubling a tirzepatide dose can cause severe nausea, vomiting, and dehydration, and self-correcting is not safe.

How do I report a malfunctioning Zepbound pen to Lilly?

Call Lilly Customer Service at 1-800-545-5979. Have the lot number (printed on the pen label), the NDC, and a description of the malfunction. They handle defect reports and replacement coordination.

Should I report a Zepbound malfunction to the FDA?

You can report voluntarily at fda.gov/medwatch. This is most useful when a malfunction caused harm or when you want to add to the FDA safety database. It is not required for routine defects.

My KwikPen will not dial to 1. What is wrong?

Either the cartridge is empty (4 doses already used) or the dose knob has failed. Confirm how many doses you have taken. If fewer than 4, contact Lilly for a replacement.

Why does my Zepbound pen feel sticky or hard to press?

A pen taken straight from the refrigerator has stiffer mechanical action. Letting it warm to room temperature for 15 to 30 minutes before injection produces smoother delivery. If the pen still feels stuck after warming, it may be defective.

Can I get a free replacement for a defective Zepbound pen?

Lilly's policy is to replace defective products on a case-by-case basis. Your pharmacy may also have a replacement protocol. Document the lot number and Lilly case number, and your insurance should not be charged for a confirmed defect.

Does Lilly want the broken pen back?

Sometimes. Lilly may ask you to return the device for failure analysis. They will provide instructions and a return container if so. Do not try to disassemble the pen.

What if my insurance refuses to cover a replacement dose?

The Lilly case number tied to the defect report can be used to challenge the insurance denial. Your pharmacy can help you submit the documentation.

Is a Zepbound pen still safe if it was in the car for a few hours?

Probably not, especially in summer or winter. Tirzepatide is sensitive to both heat and freezing. If you cannot rule out exposure outside 36 to 86°F, treat the pen as compromised and replace it.

Author / review note

Reviewed by the FormBlends Medical Team. References include the Eli Lilly Zepbound prescribing information (rev. 2024), the Zepbound single-dose pen Instructions for Use guide (Eli Lilly, 2024), the Zepbound KwikPen Instructions for Use (Eli Lilly, 2024), and the FDA Center for Drug Evaluation and Research labeling for tirzepatide.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and KwikPen are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. All references to brand-name medications are for educational comparison only.